ACRS vs VNDA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
VNDA Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Vanda Pharmaceuticals Inc. (VNDA) driven by superior Valuation, Growth & Margin, Options & Structure while ACRS counters with relative strength in Momentum & Technical. Fundamentally, ACRS trades at N/M Forward P/E with -1412.4% operating margin (-55.1% YoY revenue) versus VNDA at 103.1x Forward P/E and -77.6% operating margin (+24.1% YoY). In options structure, ACRS sits in BREAKDOWN (1st %ile IV; Dealer Gamma Walls on Pro) against VNDA sits in BREAKDOWN (75th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ACRS Revenue | VNDA Revenue | ACRS Op. Margin | VNDA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $10M | $190M | -1378.3% | 11.3% | VNDA |
| FY2019 | $0M | $230M | -2627.3% | 10.0% | VNDA |
| FY2020 | $10M | $250M | -785.4% | 11.0% | VNDA |
| FY2021 | $10M | $270M | -1327.1% | 15.7% | VNDA |
| FY2022 | $30M | $250M | -302.0% | 2.5% | VNDA |
| FY2023 | $30M | $190M | -311.6% | -7.2% | VNDA |
| FY2024 | $20M | $200M | -758.2% | -20.5% | VNDA |
| FY2025 | $10M | $220M | -975.9% | -70.0% | VNDA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ACRS | VNDA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $620.2M | $238.9M | Larger Scale | ACRS |
| Trailing P/E Ratio Valuation | N/M | 103.1x | Lower Multiple | VNDA |
| Forward P/E Ratio Valuation | N/M | 103.1x | Lower Multiple | VNDA |
| Revenue Growth (YoY) Growth | -55.1% | +24.1% | Higher Growth | VNDA |
| Operating Margin (TTM) Profitability | -1412.4% | -77.6% | Higher Margin | VNDA |
| Net Profit Margin Profitability | 0.0% | -119.9% | Higher Margin | ACRS |
| Return on Equity (ROE) Capital Efficiency | -55.5% | -82.5% | Higher ROE | ACRS |
| 52-Week Range Position Momentum | 32% ($2โ$7) | 4% ($4โ$10) | Stronger Trend | ACRS |
| Beta / 30D Volatility Risk Regime | 1.53ฮฒ ยท 73% Vol | 1.25ฮฒ ยท 61% Vol | Lower Realized Risk | VNDA |
| Unified Institutional Score Composite Signal | 38.7 / 100 (SELL) | 49.0 / 100 (HOLD) | Higher Composite | VNDA |